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Abstract: 
The human immunodeficiency virus type-1 (HIV-1) gp160 (gp120-gp41 complex) trimer envelope (ENV) protein is a potential vaccine candidate for HIV/AIDS. 
HIV-1 vaccine development has been problematic and charge polarity as well as sequence variation across clades may relate to the difficulties. Further obstacles 
are caused by sequence variation between blood and brain-derived sequences, since the brain is a separate compartment for HIV-1 infection. We utilize a three-
dimensional residue measure of solvent exposure, accessible surface area (ASA), which shows that major segments of gp120 and gp41 known structures are 
solvent exposed across clades. We demonstrate a large percent sequence polarity for solvent exposed residues in gp120 and gp41. The range of sequence polarity 
varies across clades, blood, and brain from different geographical locations. Regression analysis shows that blood and brain gp120 and gp41 percent sequence 
polarity range correlate with mean Shannon entropy. These results point to the use of protein modifications to enhance HIV-1 ENV vaccines across multiple 
clades, blood, and brain.  It should be noted that we do not address the issue of protein glycosylation here; however, this is an important issue for vaccine design 
and development.  
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Abbreviations: HIV-1 - human immunodeficiency virus type 1; AIDS - acquired immunodeficiency syndrome; ENV - envelope; gp160 - 160,000d glycoprotein; 
gp120 - 120,000d glycoprotein; gp41 - 41,000d glycoprotein; LANL - Los Alamos National Laboratories;  PDB- Protein Data Bank; HVTN - STEP HIV vaccine 
trial; AA - amino acids; MSA - multiple sequence alignment; ASA - accessible surface area;  SNPs - single nucleotide polymorphisms; HAART - Highly Active 
Antiretroviral Therapy;  CCR5 - C-C chemokine receptor type 5; CNS - central nervous system;  HIVE - HIV encephalitis;   P - polarity; NP - non-polarity; CTL - 
cytotoxic T lymphocyte. NIAID - National Institute of Allergy and Infectious Diseases  
 
 
 
Background: 
The design of an effective HIV-1/AIDS vaccine is still in development and its 
progress is debated [1]. The recent results of the HVTN 502/Merck V520-023 
study, using three recombinant adenovirus-5 (rAD5) vectors expressing Ad5-
gag, Ad5-pol and Ad5-Nef, developed jointly by NIAID and Merck 
Corporation [2] and the use of priming injections of recombinant canary pox 
vector (ALVAC-HIV) with booster injections of gp120 subunit (AIDSVAX-
B/E) in a Thailand trial [3] have stimulated further research and strategies in 
the pursuit of HIV-1 vaccines.  Studies of back-to-basics sequence structure 
relationships coupled with immunological characterization are needed and the 
HIV-1 ENV remains a key potential target for vaccine development [4-7].   
 
The study of charged AA in the ENV protein is of importance because of 
protein-protein surface interactions. These include gp120 and gp41 self- and BIOINFORMATION  open access 
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inter-subunit interactions, inner (core)-outer (solvent) molecular interactions, 
receptor and co-receptor attachment, fusion required for viral entry, and 
antibody and CTL immunity. Another key issue is that although AA sequences 
may vary widely within and among HIV-1 clades, there may be 
immunologically conserved three-dimensional structures that provide foci for 
improved vaccine development [6-10].        
 
AA positive selection is a consequence of the effects of immunity on HIV-1 
ENV evolution. In 2007, the LANL HIV sequence database was examined and 
AA positive selection sites in the ENV protein were identified. Asian isolates 
had a higher positive selection level than North American isolates. The C3, C4, 
and C5 conserved domains had most of the positive selection sites detected and 
C1 and C2 were primarily positive selection-free [11]. In other studies, 
ClustalX was used to align 300 sequences of gp160 and located AAs with a 
high degree of conservation that were in proximity to one another in three-
dimensional maps. For example, in HIV-1 clade A, conserved AA occurred at 
positions including 32, 137, 441, and 915. Several AA were classified 
according to their polarity or non-polarity at such conserved sites [12]. 
 
Each component of the gp120-gp41 complex has specific functions. For 
example, anchoring the complex occurs via the gp41, a transmembrane protein 
[13]. The gp120 V3 variable region has long been considered crucial for ENV 
function. The V3 variable region binds to CCR5 or CXCR4 cell surface 
coreceptors and contains conserved regions including a band, arch, and 
hydrophobic core [14]. HIV-1 gp41 N- and C-domains mediate virus-
membrane fusion. AA sequence residues 512-681 from 862 isolates were 
analyzed in HIV-1 clades A, B, C, D, E, F, G, H, I, J, and O. A highly 
conserved segment GIVQQQ on the C-terminal of the C-domain was identified 
that is involved in the formation of the three interfaces between neighboring 
helices in the trimer [15]. The HIV-1 gp41 amino-terminal region is a pre-
transmembrane domain. It contains an amphipathic-at-interface sequence that 
is non-polar (aromatic AA-rich), and is conserved among several viral strains. 
The amphipathic-at-interface sequence also includes a beta-turn structure with 
nonhelical extended region. Interaction of the amphipathic-at-interface 
sequence with the fusion peptide region reduces its fusion ability [16]. 
Additional studies from 357 HIV-1 clades A, B, C, and D also indicated that 
the gp41 C-terminal tail loop and three beta-sheet membrane-spanning domains 
are involved in membrane fusion [17].   
 
In addition to ENV AA sequence and charge studies, Shannon entropy is a 
measure of diversity of AA sequences; the higher the entropy the greater is 
sequence diversity [18]. For example, during investigations of HIV-1 vaccine 
development, Shannon entropy was used to assess the intra- and inter-clade 
sequence variation of proteomes of HIV-1 clades A1, B, C, and D. Mean 
entropies were compared for strings of AA sequences and used to identify 
protein regions with little diversity that harbored epitopes [19, 20]. Entropy 
was also used to pinpoint clade sequence differences. For example, between 
clades B and C for HIV-1 gp120, amphipathicity was maintained whereas there 
was elevated entropy at the polar face of the C3 region alpha2-helix. In clade B 
there was increased hydrophobicity and in clade C, V4 loops were shorter [21].  
Entropy analysis also helped identify protein regions with little AA variation 
that harbored CTL epitopes; these regions frequently occurred in alpha helices 
[19, 22]. Shannon entropy increased for V3 regions from patients treated with 
CCR5 antagonists vs. baseline. This may be due to treatment resistant viruses 
being able to produce a wider range of sequence variation than baseline viral 
strains [23].   
 
The loss of effectiveness of immunological and drug therapy against HIV-1 
and difficulties with producing an effective vaccine are due in part to viral 
immune escape and protein sequence diversity. However, a study of protein 
structure, selection, and sequence diversity of HIV-1 proteins demonstrated a 
ceiling to the diversity reachable by HIV-1 despite its high mutation rate [24, 
25]. Moreover, concomitant with the sequence variability ceiling, variability 
tended to occur at restricted locations in HIV-1 proteins including in ENV. 
Entropy studies for both clades B and C demonstrated that increased entropy 
occurred at AA sites with less constraint, and low entropy at sites with greater 
constraint. Entropies of AA sites in the protein core were lower than for sites 
on the protein surface. This is consistent with a paradigm in which loops have 
greater solvent accessibility than the more constrained core AAs. In this 
context, protein-protein interaction regions are considered solvent inaccessible 
(hydrophobic) [24, 25].  
Since the early 1990’s, phylogenetic analyses supported the paradigm of brain 
as a reservoir for HIV-1 infection sequestered from blood. In studies of the V3 
region, both polar and non-polar AA residues were prevalent for brain and 
blood with predominantly negative and neutral AA for the brain. Entropy 
calculations for HIV-1 derived from six patients indicated lower entropy in V3 
sequences from brain vs. blood.  Thus, the complex sequence and structure 
relationships for HIV-1 sequences in brain need to be dealt with as well, for 
vaccine design and production [26-32]. 
 
Materials and Methodology:   
Datasets: 
Structures: 
The structural data for gp120 (Table 1 see Supplementary material) and gp41 
(Table 2 see Supplementary material) were obtained from the PDB 
[http://www.pdb.org/pdb/home]. This dataset was created using the PDB 
interface by keyword search followed by manual curation. It should be noted 
that gp120 structures are available in the ligand-bound state.  
 
Sequences: 
Gp120 and gp41 sequences (from blood and brain) were downloaded from the 
LANL database [http://www.hiv.lanl.gov/] [33]. These sequences represent 
multiple HIV-1 clades from different geographical locations including Africa, 
Asia, North America, South America, Europe, and Oceania. Several sequences 
were also derived from the PDB structural database 
[http://www.pdb.org/pdb/home]. 
 
Sequence Alignment: 
We developed the multiple sequence alignment (MSA) for gp120 (Figure 1) 
and gp41 (Figure 2) sequences with known structures (Tables 1 and 2) in 
Protein databank (PDB). The alignment was performed using Clustal W with a 
gap-opening penalty of 10 and a gap extension penalty of 0.2 [34].   
 
Structure analysis: 
Superimposition: 
The gp120 (Table 1) and gp41 (Table 2) structures in its monomer and trimer 
states  (Figure 3) were superimposed using SPDBV (Swiss PDB Viewer 
version 3.7).   
 
Solvent Accessibility: 
The solvent accessibility of residues in gp120 and gp41 structures was assessed 
using ASA calculations (Figure 4). ASA was calculated using the Lee and 
Richards [35] algorithm implemented in the software, Surface racer [36]. The 
probe radius used was 1.4 Å for the calculation of ASA. 
 
Compositional polarity: 
We used percent compositional polarity to estimate sequence variations among 
known clades. This allows calculation of percent polarity range among clades, 
within which the sequences vary. The percent compositional polarity (S, T, N, 
Q, H, Y, D, E, R, W, C and K) and non – polarity (G, A, P, V, I, L, F, M 
residues) were calculated for gp120 and gp41, which included blood and brain 
sequences (Figure 5). It should be noted that W and C were included in the 
polar group due to their partial polar property. 
 
Shannon Entropy: 
Shannon entropy for each AA residue was calculated as –SUM {Paa.log(Paa)}. 
Paa is the proportion of each AA in its respective site [37]. This equation is 
based on a calculation of informational entropy and the LANL methods have 
been described in detail [38, 39] (http://www.hiv.lanl.gov/content 
/sequence/ENTROPY/entropy_one.html). 
 
Polarity range and Shannon Entropy relation: 
Pearson correlation of Polarity range and Shannon Entropy was calculated 
using Microsoft Excel (Figure 6). The statistical significance analysis between 
Shannon entropy and polarity of gp120 and gp41 sequences in blood and brain 
were calculated using Two Way ANOVA. In addition, the post test for linear 
trend has been applied to confirm the linear regression between the groups 
using GraphPad Prism (version 5) software. 
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Figure 1: MSA of gp120 sequence dataset (Table 1) derived from known structures from the PDB database. [http://www.pdb.org/pdb/home] The position specific 
mutations are in bold letters. The incomplete sequences in the alignment are indicated with dashes. The V1/V2, V3, V4 and V5 regions are marked. However, all 
the variable loops are not yet solved by X-ray crystallography in gp120 structures and hence their corresponding atomic coordinates are not available [40]. These 
regions are indicated with incomplete sequences. BIOINFORMATION  open access 
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Figure 2: MSA of gp41 sequence dataset (Table 2) derived from known 
structures from the PDB database. [http://www.pdb.org/pdb/home]. The 
position specific mutations are in bold letters. The incomplete sequences in the 
alignment are indicated with dashes. The gp41 structures shown consist of the 
N and C helices representing the N heptad repeat and C heptad repeat, 
respectively. 
 
 
Figure 3: Structural superimposition of (a) gp120, (b) gp120 trimer, (c) gp41, 
and (d) gp41 trimer. The gp120 and gp41 structures obtained from PDB 
[http://www.pdb.org/pdb/home] (Table 1 and Table 2) were superimposed 
using the software SPDBV (Swiss PDB Viewer version 3.7). 
[http://www.expasy.org/spdbv/]. The variable loops (V1-V5) and the constant 
regions (C1-C4) of the GP120 structure, with inner and outer domains are 
shown (a). The superimposition of the gp120 trimer (PDB ID: 3DNL), solved 
through NMR at 20.0Å is shown in (b). The N heptad and the C heptad regions 
of the superimposed gp41 structure, solved by X-ray crystallography with a 
resolution of 2.10Å, are shown in (c). Only the N heptad region of gp41 is 
available in trimeric form, as illustrated in (d). 
 
Results: 
The Graphical Abstract outlines the flow of analysis from the databases to the 
tables and figures. The LANL and PDB databases were utilized to obtain 
sequence and structure information for the HIV-1 gp120 and gp41. We 
generated datasets from PDB of known structures produced by X-ray 
crystallography for gp120 and gp41 shown in Tables 1 and 2, respectively. 
These datasets include clades B, C, and A/E for gp120, and clades B and D for 
gp41. From Tables 1 and 2, we produced MSAs for gp120 and gp41 shown in 
Figures 1 and 2, respectively. In Figure 3, the corresponding structures for the 
sequence alignments were then used for constructing structural superimposition 
of gp120 (a), its trimer (b), gp41 (c), and its trimer (d). The superimposition of 
multiple structures shows that several clades share the same structural folds for 
gp120 (clades B, C, A/E) and gp41 (clades B, D). The ASA distribution, mean, 
and standard deviations are shown for each residue position for gp120 and 
gp41 in Figure 4 based on Tables 1 and 2. These values show the degree of 
structural variation for the differences in sequence, which is represented by the 
ASA measure and help identify residue positions that are solvent exposed 
(ASA > 0 Å
2). The mean distribution show that most residues in gp120 and 
gp41 are solvent exposed.  
 
 
Figure 4: Residue position specific ASA distribution profiles for (a) gp120 and 
(b) gp41, (c) and (d) respective means, (e) and (f) respective standard 
deviations. The structural datasets were obtained from PDB 
[http://www.pdb.org/pdb/home] as shown in Tables 1 and 2. The ASA 
distribution was calculated using Surface racer [41].   
 
As of 12-31-2010, there were approximately 14,925 gp120 and 14,472 gp41 
sequences in the LANL database for clades A-K. Figure 5 shows the sequence 
percent polarity for several clades, blood, and brain by geographical location 
from this database. In addition, the sequence percent polarity range is shown 
for gp120 (clades B, C, A/E) and gp41 (clades B, D) for which structures are 
known from the PDB database. (The figures that utilize sequences from the full 
LANL database for clades A-K and the sequences from known structures from 
PDB do not specify geographical location.) The ranges in percent 
compositional polarity among clades in blood and brain sequences are shown 
in Table 3 (see Supplementary material). The polarity range of gp120 clade 
B brain vs. blood sequences is 19.47% vs. 18.0%, respectively in Europe, clade 
B brain vs. blood, 20.13% vs. 21.64%, respectively, in North America, and 
clade A brain vs. blood 17.78% vs. 19.44%, respectively, in Africa. The range 
of polarity of gp41 clade B brain vs. blood sequences is 11.81% vs. 10.27%, 
respectively in Europe, and clade B brain vs. blood, is 12.76% vs. 10.72%, 
respectively, in North America. There is a correlation for gp120 Shannon 
entropy vs. gp120 polarity range across clades and for gp41 Shannon entropy 
vs. gp41 polarity range among clades. The Pearson correlation coefficients (r) 
are 0.734 and 0.588, respectively, for gp120 and gp41 (Figure 6). Two-Way 
ANOVA of Shannon entropy and polarity of gp120 as well as gp41 sequences 
shows significant variation in both blood (F = 509.6; P<0.0001) and brain (F = 
790.9; P < 0.0001). Furthermore, the post-test for linear trend, between the 
Shannon entropy and polarity, is positively correlated by coefficient of 
determination in blood (R
2 = 0.558) and in brain (R
2 = 0.483). BIOINFORMATION  open access 
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Figure 5: Percent sequence compositional polarity (%P) and non-polarity (%NP) of gp120 and gp41 sequences.These sequences are from HIV database 
sequences, the PDB structural database (a, b) [http://www.pdb.org/pdb/home] and the LANL sequence database (c, d) [http://www.hiv.lanl.gov/]. (Geographical 
information is not available from PDB in (a) and (b) and the A-K sequence geographical information in (c) and (d) from LANL are not shown). Additional 
sequence compositional polarity comparisons are from blood (e to w) and brain (x to zb). Clade and source geographical locations are stated (from LANL). The 
numbers in parenthesis represent the number of sequences. The ranges for %P and %NP are stated as well in each figure. BIOINFORMATION  open access 
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Figure 6: Mean Shannon entropy and polarity range of gp120 and gp41 
sequences in brain and blood samples from different geographical locations.  
Shannon entropy of gp120 and gp41 sequences is calculated at the LANL 
website [http://www.hiv.lanl.gov/]. The mean Shannon entropy is correlated 
with polarity range by regression coefficient (r) of 0.734 for gp120 (a) and 
0.588 for gp41 (b) sequences. The Pearson correlation co-efficient was 
calculated using Microsoft EXCEL software. 
 
Discussion: 
The gp120-gp41 complex trimer protein is a potential HIV-1 vaccine candidate 
[42]. The gp120 and gp41 protein subunits interact with each other at an 
interface, forming a gp120-gp41 complex involved in trimer assembly. The 
gp41 interactive region of the gp120 protein has a layered structure that has 
conformational mobility – flexibility - at the interface with gp41 [43]. The 
gp120 structures in the PDB database are available only in ligand-bound states, 
which may be partly due to the limited stability of the protein without support 
ligands. The trimer is unstable when produced in vitro and this may be caused 
by its sequence composition and conformation [44-46]. The polar composition 
of the gp120-gp41 complex trimer protein influences its surface, 
immunological, and stability properties. The bottleneck for the in vitro 
synthesis and production of this protein in stable form may be the prevalence of 
solvent exposed polar residues as described in our findings. Moreover, trimer 
instability is probably also due to the difficulty in exactly mimicking the in 
vivo environment, in vitro, for protein folding and assembly of the complex. 
The structure of the gp120-gp41 complex is similar among clades and 
homologous sequences share common structural folds and shapes although 
they have differences among side chain packing and residue orientation [47, 
48]. Our analysis, using a solvent exposure measure, ASA, shows three-
dimensional structural variation for each AA position and that the residues are 
solvent-exposed. In addition, in major segments of gp120 and gp41, we 
demonstrate a large percent polarity for solvent exposed residues across clades, 
blood, and brain. Thus, our findings support more open and dynamic ENV 
structures and conformations.  
 
The variation in biochemical properties is relevant to manufacturing a stable 
and effective HIV-1 ENV protein. An additional concern in using the ENV as 
an HIV/AIDS vaccine candidate is its high sequence variation among clades 
from different geographical locations; the LANL database (as of 12-31-2010) 
contained 14,925 gp120 and 14,472 gp41 sequences. Potential gp120-gp41 
global vaccine candidates should incorporate the issue of immunological 
specificity and AA mutant variation across clades from different geographical 
locations. Our analysis of the known sequences for gp120 and gp41 to estimate 
the polarity changes caused by AA variation show that the percent polarity 
range among clades, blood, and brain correlates with the mean Shannon 
entropy. This reflects sequence variation that changes surface properties within 
and across clades, blood, and brain and this is anticipated to affect their 
respective immunological responses. Despite the structural similarities 
determined so far across clades for blood, this is not yet known for blood vs. 
brain. The difference in sequence polarity range for brain is comparable to 
blood for gp120 and is greater for brain than blood for gp41. These sequence 
variations could be due to differences in immune selection between brain and 
blood as well as due to the structure of the ENV, e.g. the gp120 juts further into 
the solvent than does gp41, since gp41 is partially submerged in the membrane. 
These findings help quantify the percent compositional polarity range within 
which the gp120 and gp41 sequences vary among clades; we infer from this 
structural folding related to conformations pertinent to the immune response. 
This is further relevant in the design of suitable HIV-1 ENV vaccines specific 
for multiple HIV-1 clades across blood- and brain-derived sequences. Vaccines 
that induce neutralizing antibody are currently insufficient to the task; thus, 
new methodologies are needed to optimize this approach. A recent method is 
under development that originates from a neutralizing antibody, works its way 
back to reconstruct the epitopes (reverse engineering), and then uses a structure 
based design technology to optimize the epitopes [49]. The structural 
information presented in this article should enhance methods that augment the 
stability of the gp120-gp41 complex and trimer. This work points to the need 
for the development of supporting ligands that assist in protein conformation 
stabilization as well as producing AA mutants and other protein modifications 
that neutralize antigen charge where needed. In addition, brain-related HIV-1 
should be dealt with as strains of HIV-1 that similarly require a specific 
antigenic enhancement approach. For this tactic, it is important to understand 
the charge characteristics of the antigen; thus, we characterize the HIV-1 ENV 
from the point of view of compositional percent charge polarity and its 
variation across clades, brain, and blood. 
 
There are several additional concerns in developing HIV-1 ENV vaccines that 
indicate the complexity of the problem and the sophistication required. These 
include issues of antigen integrity, delivery, and cross-reactivity across clade, 
blood, and brain viral strains. Furthermore, potential vaccines may have 
advantageous or deleterious effects depending on other factors as well. Such 
vaccine-related factors include host immune responses that might cause 
inflammation resulting from vaccines that could be more deleterious in the 
presence of HIV-1 infection. Thus, application of the knowledge of antigen 
structure may be different for vaccines in uninfected vs. HIV-1 infected 
individuals. Virologic and immunologic factors (e.g., pre-existing viral strains 
and cognate host immune responses), once one introduces a vaccine into the 
CNS of an infected individual, might result in further inflammation as well. 
Moreover, it is unknown how selective pressure on virus evolution might lead 
to vaccine-resistant strains that vitiate vaccine effects. Would a vaccine be 
possible that stimulates the immune response sufficiently rapidly to halt virus 
replication prior to mutant virus spread? It is also unknown about the potential 
interactions with vaccines amongst neurovirulent macrophage-tropic HIV-1 
strains (that predominantly infect the CNS).  In addition, which potential 
vaccines will inhibit or prevent their neurovirulence as well as suppress or 
prevent brain infections due to CNS strains? In host genetics for example, the 
CCR5-32-delta polymorphism results in a less or non-functional HIV-1 co-
receptor. Therefore, those individuals with that allele would be anticipated to 
have improved potential survival with a vaccine. However, NeuroAIDS 
susceptibility allele SNPs may play a deleterious role during vaccine exposure 
coupled with virus exposure, pre- or post-vaccinations. Because NeuroAIDS 
appears to result largely from host immune state and viral strain, host 
variability in the immune response to vaccine introduction is a crucial 
concomitant concern [10, 27, 29, 30, 31, 50, 51].   
 
The effects of HIV-1 infection can be directly measured in the brain and the 
neuropathology of HIVE has changed in the brain since the use of HAART 
commenced in 1995 [52]. Concomitant use of vaccines and anti-viral therapy 
may have an interactive impact on these therapies systemically and in the brain. 
The production of escape mutants could occur within brain that has been 
demonstrated systemically by automated deep sequencing techniques because 
of anti-CCR5 strain antiviral therapy [53]. During the last several years, the 
HIV-1 infected population has shown increased aging and increased incidence 
of Alzheimer’s disease and these factors may further complicate vaccine use in 
at-risk and already infected individuals [52]. An additional complicating factor 
in the use of vaccines is the possibility of autoimmunity as a component of 
increased inflammation that could occur peripherally as well as within the brain 
[54]. Finally, in this article, we do not deal with the problem of protein BIOINFORMATION  open access 
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glycosylation; however, this is an important issue in vaccine production. On the 
one hand, the virus, as an additional means of immune escape may use 
glycosylation, though contributing to immunogenicity. On the other hand, 
deglycosylation of HIV-1 ENV proteins, in vitro, may enhance their use in 
vaccines [55-58].  
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Supplementary material: 
 
Table 1:  GP120
a structural dataset from PDB [http://www.pdb.org/pdb/home]  
PDB  ID Clade  Length  (aa) Res
b 
(Å) 
Mutation Protein  Region  Reference 
3JWD B  379  2.61  -
c  Core
d  [43] 
3JWO B  357  3.51  T257S,  S375W  Core  [43] 
3LQA  C  332  3.4  T89I, N226D, T232I, N285T, S329N, T388I, N447D  Core  [59] 
3NGB 01_AE  353  2.68  -  Core  [60] 
3HI1 B  321  2.9  -  Core  [61] 
3IDX  B  317  2.5  M95W, T257S, S375W, A443M, W96C, V275C, I109C, Q428C  Core  [61] 
3IDY  B  317  3.2  M95W, T257S, S375W, A443M, W96C, V275C, I109C, Q428C  Core  [61] 
3DNL B  35     
- 
 
Core  [41] 
170 20 
83  
3DNN B  35     
- 
 
Core  [41] 
170 20 
83  
3DNO B  35     
- 
 
Core  [41] 
170 20 
83  
2I5Y B  313  2.2  -  Core  [62] 
2I60 B  313  2.4  -  Core  [62] 
2NXY B  317  2  S334A  Core  [60] 
2NXZ  B  317  2.04  T257S, S334A, S375W  Core  [60] 
2NY0  B  317  2.2  M95W, W96C, T257S, V275C, S334A, S375W, A433M  Core  [60] 
2NY1  B  317  1.99  I109C, T257S, S334A, S375W, Q428C  Core  [60] 
2NY2  B  317  2  T123C, T257S, S334A, S375W, G431C  Core  [60] 
2NY3  B  317  2  K231C, T257S, E267C, S334A, S375W  Core  [60] 
2NY4  B  317  2  K231C, T257S, E268C, S334A, S375W  Core  [60] 
2NY5  B  317  2.5  M95W, W96C, I109C, T257S, V275C, S334A, S375W, Q428C, A433M  Core  [60] 
2NY6  B  317  2.8  M95W, W96C, I109C, T123C, T257S, V275C,S334A, S375W, Q428C, 
G431C 
Core  [60] 
2NY7  B  317  2.3  M95W, W96C, I109C, T257S, V275C, S334A, S375W, Q428C, A433M  Core  [60] 
2QAD B  322  3.3  -  Core with V3  [63] 
1YYL B  313  2.75  -  Core  [64] 
1YYM B  313  2.2  -  Core  [64] 
2B4C B  344  3.3  -  Core with V3  [64] 
1RZK B  313  2.9  Variable  Loops  substituted  Core  [65] 
1G9M B  321  2.2  -  Core  [66] 
1G9N B  313  2.9  -  Core  [66] 
1GC1 B  321  2.5  (GARS)
e Substitution at N Terminus, Gly/Ala/Gly substitution for V1/V2 and 
V3 Loops 
Core  [9] 
aGP120 = Larger subunit of ENV glycoprotein; 
bRes = Atomic resolution of PDB structure; 
cno information available; 
dCore region of gp120; 
eGARS = Glycine, 
Alanine, Arginine, Serine.  
 
Table 2: GP41 structural dataset from PDB [http://www.pdb.org/pdb/home]  
PDB ID  Clade  Length (aa)  Res 
a(Å) Mutation  Protein  region  Reference 
1AIK B 
bN=37;
cC=35 2.0  -
d Core
e  [67] 
1DF4 B  68  1.45  -  Core  [68] 
1DF5 B  68  2.7  -  Core  [68] 
1DLB B  68  2.0  Q65L  Core  [69] 
1ENV  B  123  2.6  V61, L9I, N13I, L16I, V20I, L23I, V27I  Ectodomain
f  [70] 
1FAV  B  79  3  V6I, L9I, N13I, L16I, V20I, L23I, V27I  Trimeric core  [71] 
1I5X B  68  1.8  R579A  Core  [72] 
1I5Y B  68  2.1  G572A  Core  [72] 
1K33 B  68  1.75  I48A  Core  [73] 
1K34 B  68  1.88  I55A  Core  [73] 
1QR8 B  68  2.1  W571R  Core  [74] 
1QR9 B  68  1.6  -  Core  [74] 
1SZT B  68  2.4  -  Thermostable  subdomain  [70] 
2CMR  D  226  2  -  Inner core mimetic 5-helix  [75] 
2OT5 B  68  1.8  N43D  Core  [23] 
2ZZO  B  N=37;C=35  2.2  S138A in C  Fragment N36 and fusion 
inhibitor C34/S138A 
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3CP1 B  86  2  N43D  Core  domain  [23] 
3CYO B  86  2.1  N554D,E648K  Core  domain  [23] 
3F4Y  B  N=38; C=40  2  M1T, M4E, E5A, E9A, N11A, N12E, T14A, S15A, L16R, 
H18E, S19A, N21E, Q33A, E34A, L36R in C 
Six-helix bundle   [77] 
3F50 B  38  2.8  -  Six-helix  bundle  [77] 
3G7A B  36  2.8  -  Six-helix  bundle  [77] 
3K9A B  108  2.1  HR1+4XGly+HR2+MPER
g Ectodomain  [78] 
3P30 B  96  3.3  -  Ectodomain  [79] 
aRes= Atomic resolution of PDB structure; 
bN= N terminal of gp41; 
cC= C terminal of gp41; 
dno information available; 
eCore = Core structure of gp41;  
fEctodomain of gp41; 
gMPER= Membrane-proximal external region 
  
Table 3: The range of compositional polarity for ENV, GP120 and GP41 structures from PDB [http://www.pdb.org/pdb/home] and sequences from LANL 
[http://www.hiv.lanl.gov/]  
     Region
a  Clade  Number of sequences  Range
b of % compositional polarity 
GP120  Sequences  −
c A-K  14,925  29.21 
Structures
d  − B,C,A/E  30  1.90 
Blood Sequences  Africa  A  25  19.44 
Africa C  21  19.18 
Africa F1  9  14.98 
Africa G  9  17.30 
Asia C  12  13.85 
South America  D  3  15.68 
North America  B  138  21.64 
Europe A  6  18.01 
Europe B  3  18.00 
Brain Sequences  Africa  A  6  17.78 
Europe B  78  19.47 
North America  B  255  20.13 
GP41  Sequences
e  − A-K  14,472  20.71 
Structures
f  − B,D  23  23.40 
Blood 
Sequences 
Africa A1  9  13.41 
Africa C  15  11.64 
Africa F1  9  14.98 
Africa G  9  17.3 
Oceania A1  6  8.8 
Asia C  12  9.49 
Europe A1  6  9.89 
Europe B  12  10.27 
North America  B  21  10.72 
South America  D  3  12.61 
Brain Sequences  Europe  B  75  11.81 
North America  B  222  12.76 
aRegion = sample source geographical location; 
bRange = Maximum % compositional polarity - Minimum % compositional polarity; 
cNo geographical locations 
specified; 
dgp120 sequences based on structures from PDB; 
egp41 sequences from LANL; 
fgp41 sequences based on structures from PDB 
  